MET and non-small cell lung carcinoma: Amivantamab, the first approved EGFR and MET bispecific antibody for treating locally advanced or metastatic NSCLC with EGFR exon 20 insertion (ex20ins) mutations, has garnered attention for its promising clinical prospects in recent years2.